

# Carbon Reduction Plan

**Supplier name:** Haemonetics Limited, a subsidiary of Haemonetics Corporation

**Publication date:** July 28, 2023

## Commitment to achieving Net Zero

Haemonetics Limited has adopted a plan to achieve Net Zero emissions for Haemonetics' UK geographic operations by 2050.

Currently, Haemonetics' UK operations include one office and a small fleet of sales vehicles.

## Baseline Emissions Footprint

Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions.

Baseline emissions are the reference point against which emissions reduction can be measured. Fiscal years are referred to throughout this plan as "FY".

<b>Baseline Year:</b> FY2018 (began on April 2, 2017 and ended on March 31, 2018)	
<b>Additional Details relating to the Baseline Emissions calculations.</b>  Scope 1 and Scope 2 baseline emissions were calculated for Haemonetics Corporation's global footprint from FY2018 to FY2022. All calculations were aligned with the Greenhouse Gas Protocol methodology. Historical Scope 3 emissions have not been calculated.  The choice of a FY18 baseline is aligned with Haemonetics Corporation's global reporting in the company's 2022 Corporate Responsibility Report, which is available on its website at <a href="http://www.haemonetics.com">www.haemonetics.com</a> .	
<b>Baseline year emissions:</b>  In FY18, Haemonetics' UK geographic operations consisted of two small R&D/manufacturing facilities and a small fleet of sales vehicles.	
<b>EMISSIONS</b>	<b>TOTAL (tCO<sub>2</sub>e)</b>
<b>Scope 1</b>	56 tCO <sub>2</sub> e
<b>Scope 2</b>	388 tCO <sub>2</sub> e
<b>Scope 3 (Included Sources)</b>	Not available. Historical Scope 3 emissions have not been calculated, however a FY22 or FY23 baseline will be established for this category. See note in Current Emissions Reporting.

<b>Total Emissions</b>	444 tCO <sub>2</sub> e
------------------------	------------------------

## Current Emissions Reporting

<p><b>Reporting Year:</b> FY2022 (began on April 4, 2021 and ended on April 2, 2022)</p> <p>In FY22, Haemonetics' UK geographic operations consisted of one small office building and a small fleet of sales vehicles.</p> <p>FY23 emissions reporting for the period that began on April 3, 2022 and ended on April 1, 2023 will be calculated pending data consolidation. This Carbon Reduction Plan will be updated once FY23 emissions reporting is available. All calculations are aligned with the Greenhouse Gas Protocol methodology.</p>	
<b>EMISSIONS</b>	<b>TOTAL (tCO<sub>2</sub>e)</b>
<b>Scope 1</b>	52 tCO <sub>2</sub> e
<b>Scope 2</b>	19 tCO <sub>2</sub> e
<b>Scope 3 (Included Sources)</b>	Haemonetics is currently working with a third party to calculate a global scope 3 emissions inventory. Scope 3 emissions within the UK geographic boundary will be calculated and reported for the following categories: Upstream Transportation & Distribution, Waste Generated in Operations, Business Travel, and Employee Commuting. Scope 3 emissions from Downstream Transportation & Distribution are likely de minimis. This Carbon Reduction Plan will be updated when Scope 3 emissions reporting is available.
<b>Total Emissions</b>	71 tCO <sub>2</sub> e

## Emissions reduction targets

To continue our progress to achieving Net Zero, we have adopted the following carbon reduction targets:

Significant Scope 1 and Scope 2 emissions reductions (84%) have already taken place between baseline FY18 and FY22 (see Completed Carbon Reduction Initiatives below). We project that these carbon emissions will decrease over the next five years to 58 tCO<sub>2</sub>e by FY28. This is an additional reduction of 3% relative to the FY18 baseline. Accordingly, we are projecting the total reduction from baseline by FY28 will be 87%.

In the long-term, Haemonetics Limited is committed to achieving Net Zero for Haemonetics' UK operations by 2050, a reduction of 100% from the applicable 2018 baseline.

## Carbon Reduction Projects

### Completed Carbon Reduction Initiatives

Between FY2018 and FY2022, Haemonetics' UK scope 1 and Scope 2 emissions decreased by 84%. This is largely due to a transition of business operations from manufacturing to sales within the UK. This is a part of Haemonetics' global effort to undertake restructuring-type activities designed to capture efficiencies, enhance commercial capabilities, align our resources and offer our customers better solutions.

### Future Carbon Reduction Initiatives

In the future we hope to implement further measures such as:

For Scope 1 & 2 emissions:

- Procure renewable electricity
- Implement energy efficiency projects (lighting, HVAC, insulation, etc.)
- Electrify the sales vehicle fleet and procure additional renewable electricity
- Work with our lessors to transition from fossil fuel HVAC to electric equipment

For Scope 3 emissions:

- Engage with transportation suppliers to set emissions reduction targets
- Reduce municipal waste by recycling and other diversion measures
- Reduce business travel mileage and utilize less intense means of transport
- Encourage lower impact means of commuting, such as biking, public transport, or working virtually

## Declaration and Sign Off

This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the Greenhouse Gas Reporting Protocol corporate standard<sup>1</sup> and uses the appropriate Government emission conversion factors for greenhouse gas company reporting<sup>2</sup>.

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard<sup>3</sup>.

This Carbon Reduction Plan has been reviewed and signed off by the board of directors (or equivalent management body).

---

<sup>1</sup><https://ghgprotocol.org/corporate-standard>

<sup>2</sup><https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting>

<sup>3</sup><https://ghgprotocol.org/standards/scope-3-standard>

**Signed on behalf of the Supplier:**

/s/ James D'Arecca

.....

James D'Arecca, Member of Board of Directors of Haemonetics Limited

Date: July 28, 2023